Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer

PARP inhibitors (PARPi) have emerged as a promising targeted therapeutic intervention for metastatic castrate-resistant prostate cancer (mCRPC). However, the clinical utility of PARPi is limited to a subset of patients who harbor aberrations in the genes associated with the homologous recombination...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Anjali, Biswas, Tanay, Praveen, Ayush, Ganguly, Promit, Bhattacharyya, Ankita, Verma, Ayushi, Datta, Dipak, Ateeq, Bushra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561629/
https://www.ncbi.nlm.nih.gov/pubmed/37812088
http://dx.doi.org/10.1158/2767-9764.CRC-23-0089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561629/
https://www.ncbi.nlm.nih.gov/pubmed/37812088
http://dx.doi.org/10.1158/2767-9764.CRC-23-0089

Ejemplares similares